SEC Form 4 · accession 0001708138-17-000013
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Terifay
Officer — EVP Commercial
Period of report
Aug 10, 2017
Accepted (ET)
Aug 11, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2017 | M | 1,921 | $52.03 | A | 25,214 | D | |
| Common Stock | holding | — | — | — | 1,699 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $52.03 | Aug 10, 2017 | M | 1,921 | D | — | Dec 16, 2021 | Common Stock | 1,921 | 0 | D |
Explanation of responses
- F1The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.